About iShares Trust - iShares Biotechnology ETF

The iShares Nasdaq Biotechnology Index Fund operates as a non diversified series fund of ishares Trust, which is an open-end management investment company. The Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of the NASDAQ Biotechnology Index (the Index). The Fund invests in a representative sample of securities included in the Index. Barclays Global Fund Advisors serves as the Fund's investment adviser. Major Holdings As of July 24, 2007, the Fund’s major holdings included Amgen, Inc.; Gilead Sciences, Inc.; Celgene Corp.; Teva Pharmaceutical; Biogen Idec, Inc.; Genzyme Corp.; Shire Plc; Vertex Pharmaceuticals, Inc.; Warner Chilcott, Ltd.; and Amylin Pharmaceuticals, Inc. Investment Portfolio As of July 24, 2007, the Fund’s investment portfolio included Medical-Biomedical/Gene; Therapeutics; Medical-Drugs; Medical-Generic Drugs; Drug Delivery Systems; Diagnostic Equipment; Medical Instruments; Medical Products; Research & Development; and Energy-Alternate Sources. History The iShares Nasdaq Biotechnology Index Fund was founded in 1999.